Updated:
Novus Bioventures
Novus Bioventures was founded in Grand Rapids, Michigan, operating as a multi-family office that pools capital from several undisclosed families.
Novus Bioventures
Novus Bioventures was founded in Grand Rapids, Michigan, operating as a multi-family office that pools capital from several undisclosed families. The firm's location in a region with a growing biotech ecosystem—anchored by institutions like the University of Michigan—shapes its investment focus. Wealth origin for the underlying families is not publicly disclosed. The firm invests across biotech and life sciences, targeting early-stage companies from pre-seed through Series A. Its portfolio includes companies such as Asha Therapeutics, a precision oncology platform, and Repertoire Immune Medicines, which works on T-cell receptor technology. The firm also holds positions in Therini Bio, a neurologic disease therapy developer, and via its partnership with BioInnovation Capital. Geographic focus is heavily Midwest, with occasional syndicated deals on the coasts. Team size and AUM are not publicly reported. Novus Bioventures maintains four Michigan offices in Grand Rapids, Farmington Hills, Ann Arbor, and Kalamazoo—suggesting a distributed operational model. The firm does not disclose a separate philanthropic vehicle, though proximity to health systems may indicate mission-related ties. No recent dated operational events are publicly verifiable. A structural differentiator is Novus Bioventures' geographic concentration. Few multi-family offices outside major coastal hubs focus solely on venture-stage life science. The firm's four-office Michigan footprint suggests a strategy of sourcing deal flow from regional research institutions rather than competing in saturated markets.
General information
Firm type
Multi Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Grand Rapids
Corporate office
Grand Rapids, MI, United States
Additional offices
Farmington Hills · Ann Arbor · Kalamazoo
Sector focus
Frequently asked questions
Who manages investment decisions at Novus Bioventures?
Novus Bioventures does not publicly name its managing principals or investment committee members. Based on its multi-family office structure, decision-making likely resides with a small team of investment professionals and the participating families. No formal CIO or CEO is listed in public records.
How does Novus Bioventures source proprietary deal flow?
The firm sources deal flow from Michigan research universities, particularly the University of Michigan, and through its relationship with BioInnovation Capital. The four-office footprint across the state allows local engagement with startup founders and academic spinouts.
Is Novus Bioventures structured as a single family office or does it operate as a multi-family office?
Novus Bioventures operates as a multi-family office, pooling capital from several undisclosed families. It does not manage capital for a single wealth origin, which distinguishes it from a single-family office. Its distributed Michigan offices support this model.
Does Novus Bioventures participate in fund commitments or only direct deals?
The firm appears to focus on direct co-investments and syndicated deals rather than committing to external funds. Its partnership with BioInnovation Capital suggests a willingness to co-invest alongside other venture investors.
What investment stages does Novus Bioventures typically target?
Novus Bioventures targets early-stage life science and biotech companies, from pre-seed and seed through Series A. Portfolio companies such as Asha Therapeutics and Therini Bio align with this stage focus.
Which sectors does Novus Bioventures explicitly avoid?
The firm does not publicly list sectors it avoids. Given its concentration in life sciences, it likely excludes software, fintech, and consumer-facing industries, though this is not confirmed.
Where does the underlying wealth come from at Novus Bioventures?
The source of wealth for the families backing Novus Bioventures is not publicly disclosed. No named principals or family names are associated with the firm in available records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: